Clinical Trial

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Study acronym: CHAPTER-3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-10-31; most recent amendment 2026-02-12.
Status change: Recruiting → Active, Not Recruiting 2026-02-12
Status change: Not Yet Recruiting → Recruiting 2025-01-16
Trial Details
NCT Number NCT06669754
Lead Sponsor Pharvaris Netherlands B.V.
Conditions Hereditary Angioedema (HAE)
Enrollment 81 participants
Start Date 2024-12-01
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-13